Últimas noticias sobre CareDx (NASDAQ:CDNA) Bolsa

CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

CareDx Inc

CANADIAN TIRE LTD A by Canadian Tire Corp. Ltd.

Canadian Tire Corp Ltd

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.
The Dow traded down 0.30% to 42,937.44 while the NASDAQ fell 0.84% to 18,347.17. The S&amp;P 500 also fell, dropping, 0.43% to 5,834.67.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41331971/how-to-earn-500-a-month-from-morgan-stanley-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Real estate shares jumped by 2% on Tuesday.
In trading on Tuesday, energy shares fell by 2.3%.
Top Headline
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported upbeat results for its third quarter.
The company posted adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus of $22.16 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares shot up 21% to $13.78 after the company announced it signed a signed a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under the CHIPS and Science Act.</li>
<li>Shares of MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) got a boost, surging 14% to $5.28 after safety and tolerability was confirmed in its gene therapy study for Parkinson&#8217;s.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares were also up, gaining 13% to $8.56 following a third-quarter earnings beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 43% to $1.4050. Seelos Therapeutics announced notice of delisting from Nasdaq and transfer of listing to Over-the-Counter Market.</li>
<li>Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) were down 14% to $26.85 as the company reported preliminary results for the third quarter.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) was down, falling 14% to $0.1070 after the company announced a 1-for-50 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded down 4.5% to $70.54 while gold traded up 0.4% at $2,676.80.
Silver traded up 1.2% to $31.69 on Tuesday, while copper fell 1.6% to $4.3360.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 slipped 0.80%, Germany's DAX slipped 0.11% and France's CAC 40 fell 1.05%. Spain's IBEX 35 Index rose 0.67%, while London's FTSE 100 fell 0.52%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index falling 3.67%, China's Shanghai Composite Index dipping 2.53% and India's BSE Sensex falling 0.19%.
Economics
The NY Empire State Manufacturing Index declined to -11.9 in October from 11.5 in the previous month and topping market estimates of 3.8.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a></li>
</ul>

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CDNA

ERIC

MGTX

PEGY

SEEL

WOLF

Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 89.0% to $1.43 during Tuesday's regular session. The company's market cap stands at $14.4 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares moved upwards by 29.25% to $0.07. The company's market cap stands at $8.2 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares moved upwards by 20.69% to $8.34. The market value of their outstanding shares is at $49.1 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares increased by 20.43% to $2.41. The company's market cap stands at $71.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock moved upwards by 19.81% to $5.26. The market value of their outstanding shares is at $64.2 million. </li>
<li>Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) stock moved upwards by 18.36% to $3.03. The market value of their outstanding shares is at $16.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares declined by 45.3% to $1.34 during Tuesday's regular session. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 15.93% to $0.27. The company's market cap stands at $5.8 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock decreased by 15.26% to $2.69. The company's market cap stands at $78.9 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares decreased by 15.08% to $26.59. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 14.73% to $2.2. The market value of their outstanding shares is at $4.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares decreased by 14.69% to $3.83. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APRE

DWTX

GRTS

IMRX

MYNZ

NIVF

RANI

RBOT

XCUR

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Tuesday.
The Dow traded down 0.40% to 42,894.69 while the NASDAQ fell 0.93% to 18,331.05. The S&amp;P 500 also fell, dropping, 0.44% to 5,833.93.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41331971/how-to-earn-500-a-month-from-morgan-stanley-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Real estate shares jumped by 1.5% on Tuesday.
In trading on Tuesday, energy shares fell by 2%.
Top Headline
Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reported revenue of $12.70 billion for the third quarter, beating the consensus of $11.87 billion.
Sales increased 7% Y/Y, reflecting higher net revenues in Global Banking &amp; Markets and Asset &amp; Wealth Management, partially offset by lower net revenues in Platform Solutions. The U.S. financial services giant reported EPS of $8.40, beating the consensus of $7.03.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares shot up 27% to $14.41 after the company announced it signed a signed a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under the CHIPS and Science Act.</li>
<li>Shares of MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) got a boost, surging 13% to $5.24 after safety and tolerability was confirmed in its gene therapy study for Parkinson&#8217;s.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares were also up, gaining 11% to $8.35 following a third-quarter earnings beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 52% to $1.1663. Seelos Therapeutics announced notice of delisting from Nasdaq and transfer of listing to Over-the-Counter Market.</li>
<li>Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) were down 17% to $25.93 as the company reported preliminary results for the third quarter.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) was down, falling 18% to $0.1028 after the company announced a 1-for-50 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded down 4.9% to $70.19 while gold traded up 0.4% at $2,676.10.
Silver traded up 1.2% to $31.700 on Tuesday, while copper fell 1.4% to $4.3425.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 slipped 0.40%, Germany's DAX slipped 0.01% and France's CAC 40 fell 1.10%. Spain's IBEX 35 Index rose 0.64%, while London's FTSE 100 fell 0.37%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index falling 3.67%, China's Shanghai Composite Index dipping 2.53% and India's BSE Sensex falling 0.19%.
Economics
The NY Empire State Manufacturing Index declined to -11.9 in October from 11.5 in the previous month and topping market estimates of 3.8.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a></li>
</ul>

Earnings

Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 10 points on Tuesday.
Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) fell sharply in today's pre-market trading as the company <a href="https://www.benzinga.com/quote/CDNA/news">reported preliminary results for the third quarter.</a>
CareDx said it expects third-quarter revenue of $82 million to $83 million, up approximately 23% year over year.
CareDx shares dipped 9% to $28.50 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Qurate Retail, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEB#NASDAQ">QRTEB</a>) shares dipped 47.7% to $2.14 in pre-market trading. Qurate Retail will host a conference call to discuss results for the third quarter on Thursday, Nov. 7.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) shares fell 9.7% to $2.04 in pre-market trading after declining around 7% on Monday.</li>
<li>Landsea Homes Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) shares declined 7.4% to $10.50 in pre-market trading.</li>
<li>Himalaya Shipping Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NYSE">HSHP</a>) shares fell 6.2% to $7.42 in pre-market trading.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) shares fell 6.2% to $2.90 in pre-market trading.</li>
<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) shares fell 6.1% to $7.05 in pre-market trading.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) shares fell 6% to $41.52 in pre-market trading. Shares of US-listed Chinese stocks traded lower after China&#8217;s September exports missed estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41327296/jim-cramer-is-worried-about-this-plane-maker-says-palo-alto-is-a-good-one">Jim Cramer Is Worried About This Plane Maker, Says Palo Alto Is A &#8216;Good&#8217; One</a></li>
</ul>

Pre-Market Outlook

HSHP

JFIN

LSEA

ORGO

QRTEB

CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

WIIM

CareDx shares are trading lower. The company reported preliminary Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares moved upwards by 42.6% to $0.08 during Tuesday's pre-market session. The company's market cap stands at $9.0 million. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) shares increased by 21.34% to $0.99. The company's market cap stands at $6.8 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares increased by 19.89% to $0.49. The company's market cap stands at $3.9 million. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock rose 19.73% to $0.49. The company's market cap stands at $4.4 million. </li>
<li>Oncternal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) stock rose 16.83% to $1.23. The company's market cap stands at $3.6 million. </li>
<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) shares moved upwards by 12.5% to $1.35. The company's market cap stands at $19.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 11.8% to $0.42 during Tuesday's pre-market session. The company's market cap stands at $2.0 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) stock declined by 9.91% to $2.82. The market value of their outstanding shares is at $28.9 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock declined by 9.38% to $0.29. The company's market cap stands at $6.3 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares decreased by 9.17% to $28.44. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) stock decreased by 8.62% to $2.44. The company's market cap stands at $127.7 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares decreased by 7.92% to $0.27. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

ENVB

HOTH

LIPO

NVOS

ONCT

VRPX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<ul>
<li>Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year.</li>
<li>Testing services revenue is expected to be in the range of $60 million to $61 million, an increase of approximately 26% year-over-year. This includes approximately $1.2 million in revenue for tests performed in prior quarters.</li>
<li>Patient and Digital Solutions revenue is expected to be approximately $11.9 million, and Products is expected to be approximately $10.2 million, up 20% and 7% year-over-year, respectively.</li>
<li>Ended the quarter with cash, cash equivalents, and marketable securities of approximately $240 million with no debt.</li>
</ul>

Health Care

General

CareDx Expects Third Quarter 2024 Revenue Of $82M-$83M, Up Approximately 23% YoY, Versus Consensus Of $79.53M

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;
<h3>1. Teladoc Health</h3>
Market Cap: $1.4 Billion
Focus Area: Telehealth&nbsp;
Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.
What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.
<h3>2. WELL Health Technologies</h3>
Market Cap: $1.1 Billion
Focus Area: Digital Health Solutions&nbsp;
WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;
WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.
<h3>3. Omnicell</h3>
Market Cap: $1.9 Billion
Focus Area: Automation and analytics
Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.
What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.
<h3>4. IRadimed Corporation&nbsp;</h3>
Market Cap: $700 Million
Focus Area: MRI-Compatible Devices
IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.
With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.
<h3>5. Evolent Health Inc.</h3>
Market Cap: $1.3 Billion
Focus Area: Value-Based Care
Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.
With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.
<h3>6. CareDx, Inc.</h3>
Market Cap: $520 Million
Focus Area: Transplant Diagnostics
CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.
CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.
<h3>7. Tactile Systems Technology, Inc.</h3>
Market Cap: $450 Million
Focus Area: Chronic Disease Management
Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.
Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.
<h4>Conclusion:</h4>
the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Small Cap

IRMD

OMCL

TCMD

TDOC

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

Management

CareDx Has Appointed Jing Huang, In The Newly Created Role Of Chief Data And Artificial Intelligence Officer, Huang Will Lead Key Data Science Initiatives That Are A Part Of The Company's Long-term Strategic Growth Plan

In a Court document unsealed on October 7, 2024, the DOJ indicated that it is declining to intervene in a qui tam action filed by a former CareDx employee.
Today&#39;s decision by the DOJ follows the decision made by the U.S. Securities and Exchange Commission (SEC) in September 2023 to close its investigation and take no action against the Company.
The Company believes the closure of the DOJ&#39;s investigation underscores that the underlying allegations, which have now been reviewed by two separate government agencies, were meritless, reinforcing its confidence in the integrity of its operations.
The qui tam complaint, which was filed under seal on February 12, 2021, in the federal district court for the Eastern District of New York, is now unsealed. CareDx will continue to vigorously defend itself should the former employee choose to proceed with this litigation.

Legal

CareDx Says DOJ Has Concluded Its Investigation With No Finding Of Wrongdoing And Declined To Take Any Further Action; Plans To Defend Itself Should The Former Employee Choose To Proceed With Litigation

CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024.

CareDx Names Keith Kennedy As COO And Jessica Meng As Chief Commercial Officer

Wells Fargo analyst Brandon Couillard initiates coverage on CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Underweight rating and announces Price Target of $28.

Price Target

Initiation

Analyst Ratings

Wells Fargo Initiates Coverage On CareDx with Underweight Rating, Announces Price Target of $28

In the last three months, 4 analysts have published ratings on CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.5, a high estimate of $40.00, and a low estimate of $16.00. Witnessing a positive shift, the current average has risen by 64.45% from the previous average price target of $17.33.
<img src="https://www.benzinga.com/files/images/story/2024/1724076012_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CareDx. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CareDx's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CareDx's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into CareDx's Background</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>CareDx: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: CareDx displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 31.26%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CareDx's net margin excels beyond industry benchmarks, reaching -1.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): CareDx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.54%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CareDx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: CareDx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About CareDx

BTIG analyst Sung Ji Nam upgrades CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) from Neutral to Buy and announces $40 price target.

Upgrades

BTIG Upgrades CareDx to Buy, Announces $40 Price Target

CareDx shares are trading higher after the CMS retired a draft policy that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection.

CareDx Announces CMS Retires Draft Policy Restricting Coverage, Restoring Longstanding Coverage For AlloSure, AlloMap, And HeartCare Through Surveillance Testing For Allograft Rejection

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $16 to $26.

Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $26

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $22 to $32.

Craig-Hallum Maintains Buy on CareDx, Raises Price Target to $32

HC Wainwright &amp; Co. analyst Yi Chen reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on CareDx

Shares of Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/24/07/40082489/carvana-q2-earnings-revenue-beat-eps-beat-vehicle-sales-jump-33-upbeat-guidance-and-more">second-quarter financial results</a>.
Carvana reported second-quarter revenue of $3.41 billion, beating the consensus estimate of $3.244 billion, according to Benzinga Pro. The used car retailer reported quarterly earnings of 14 cents per share, beating analyst estimates for a loss of 12 cents per share.
Carvana shares jumped 13.4% to $151.12 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 55.2% to $0.1568 in pre-market trading after falling 7% on Wednesday.</li>
<li>Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) gained 37.2% to $1.55 in pre-market trading after the company announced that IMM-1-104 was granted Fast Track designation from the FDA.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) rose 23% to $24.58 in today's pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) jumped 22.1% to $17.91 in pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares gained 20.8% to $2.61 in pre-market trading after gaining 23% on Wednesday.</li>
<li>Olo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) shares gained 19.1% to $5.69 in pre-market trading after the company reported better-than-expected second-quarter sales results.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) shares rose 17.5% to $8.31 in pre-market trading following upbeat quarterly results.</li>
<li>Kaixin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares gained 17.5% to $0.1308 in pre-market trading after the company announced it received a non-compliance notification from the Nasdaq.</li>
<li>Rush Street Interactive, Inc. (NYSE RSI) shares rose 16.8% to $11.69 in pre-market trading after the company reported better-than-expected second-quarter earnings and raised FY24 revenue forecast.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) shares dipped 25.8% to $3.56 in pre-market trading. The company announced it will host an investor call and webcast to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.</li>
<li>noco-noco Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares fell 21.9% to $0.2240 in pre-market trading after jumping 88% on Wednesday.</li>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares declined 18.9% to $8.19 in pre-market trading after the company reported second-quarter results.</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) fell 16.7% to $7.70 pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares declined 16.3% to $7.89 in pre-market trading following weak quarterly sales results.</li>
<li>Tenable Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) shares fell 14% to $39.51 in pre-market trading after the company reported second-quarter financial results.</li>
<li>Standard Biotools Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) dipped 12.9% to $1.95 in pre-market trading after the company posted weak second-quarter results.</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) shares declined 11.1% to $22.24 in pre-market trading after the company reported second-quarter financial results and issued third-quarter EPS guidance below estimates.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares fell 9.6% to $130.28 in pre-market trading following weak second-quarter guidance.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) fell 6.3% to $ 62.81 in today's pre-market trading after the company reported its fourth-quarter financial results.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/markets/24/07/40067769/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 4% Dividend Yields</a></li>
</ul>

ALXO

ATEC

BBLG

CFLT

CVNA

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

KXIN

NCNC

NOVA

TENB

UDMY

Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Hedge funds pile into healthcare stocks amid dip, Goldman Sachs says

Interest Rate Regimes And ARKG: Underperformance Explained

CareDx says DOJ has closed investigation, no wrongdoing found

Mark Massaro, an analyst from BTIG, reiterated the Buy rating on CareDx (CDNA – Research Report). The associated price target remains the same with...

Buy Rating on CareDx: A Positive Outlook Amidst Legal Resolutions and Growth Potential

Craig-Hallum analyst William Bonello maintained a Buy rating on CareDx (CDNA – Research Report) today. The company's shares closed yesterday at $28...

Craig-Hallum Keeps Their Buy Rating on CareDx (CDNA)

CareDx stock climbs 7% amid reports Natera not pursuing litigation

Capitulation in biotech is near, as well as a rally – Piper Sandler

CareDx guides Q3 revenue above estimates

CareDx ( ($CDNA) ) has provided an announcement. CareDx, Inc., a leader in precision medicine for transplant patients, has announced its preliminar...

CareDx Reports Strong Q3 2024 Revenue Growth

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on CareDx (CDNA – Research Report). The company's shares clos...

Craig-Hallum Remains a Buy on CareDx (CDNA)

AQST

ARKG

ASMB

AXGN

CLOV

CRMD

CRSP

DTIL

EXAS

EXEL

IBBQ

IDNA

IONS

MESO

NTLA

NTRA

PACB

PRAX

PSNL

PTGX

RMTI

RXRX

SDGR

SPRY

TRDA

TWST

Press Releases

CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing

CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing

CareDx to Host Investor Day on October 15, 2024

CareDx Appoints Jing Huang Chief Data and AI Officer

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

Comments

CareDx

Noticias

Últimas noticias sobre CareDx (NASDAQ:CDNA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL